Document is current
Any future updates will be listed below
-
Authors
Dijkstra, Francis https://orcid.org/0000-0001-5804-0708
O’Donnell, Patricio
Klaassen, Erica
Buhl, Derek https://orcid.org/0000-0003-4433-7150
Asgharnejad, Mahnaz
Rosen, Laura
Zuiker, Rob https://orcid.org/0000-0001-5604-0157
van Gerven, Joop
Jacobs, Gabriël
- License Information
-
More Information
Article History
Received: 14 June 2022
Revised: 17 August 2022
Accepted: 1 September 2022
First Online: 24 September 2022
Competing interests
: PO, DB, MA and LR are all (former) employees of Takeda Pharmaceutical Company, Ltd and own stock or stock options. The other authors have nothing to declare.
: The study was approved by the Medical Ethics Committee foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO) and was registered at ClinicalTrials.gov (NCT03792672). The study was performed according to International Conference on Harmonisation Good Clinical Practice guidelines, as laid down in the Declaration of Helsinki and its latest amendments. Written informed consent was obtained from all participants before any study-related activities were performed. The study was performed at the Centre for Human Drug Research, Leiden, the Netherlands from 23 January 2019 to 18 June 2019.
